The startup specializes in cancer diagnostics and drug development through membrane-bound protein technology that enhances the attachment of proteins to natural killer (NK) cell membranes. This approach aims to minimize immune-related side effects while preserving NK cell activity in cell therapy treatments.
Funding
$15.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer diagnostic methods often fail to capture the full spectrum of circulating tumor cells (CTCs), hindering comprehensive analysis and personalized treatment strategies. Existing technologies may also suffer from cell loss during processing, compromising the accuracy of downstream analysis.
Solution
CTCELLS is a cancer diagnostics and drug development company that provides tools for isolating and analyzing circulating tumor cells (CTCs). The company's CTCeptor is a fully automated system that utilizes continuous centrifugal microfluidics (CCM) technology to isolate all types of CTCs, regardless of size or marker expression. The system is complemented by HyPICC technology, a hydrogel pellicle for lossless immunocytochemistry, which minimizes cell loss during staining, ensuring accurate single-cell selection and enabling advanced multi-omics diagnostics for personalized cancer treatment. CTCELLS' approach aims to improve patient outcomes by matching cancer characteristics with the most suitable therapies.
Target Audience
CTCELLS serves researchers, clinicians, and pharmaceutical companies focused on cancer diagnostics, liquid biopsy, and personalized medicine.
Features
- Fully automated CTC isolation using continuous centrifugal microfluidics (CCM) technology
- Negative selection method selectively removes blood cells for total CTC isolation
- HyPICC technology minimizes cell loss during staining, exhibiting over 97% retention rate
- Isolates the full spectrum of circulating rare cells (CRCs), including small CTCs and cfDNA
- Facilitates advanced, personalized multi-omics diagnostics
- Streamlines the separation of rare cells with one-touch automation